These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. T effectors outfox T regulators in autoimmunity. Prod'homme T; Weber MS; Zamvil SS Nat Med; 2007 Apr; 13(4):411-3. PubMed ID: 17415374 [No Abstract] [Full Text] [Related]
43. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. Derfuss T; Linington C; Hohlfeld R; Meinl E J Mol Med (Berl); 2010 Aug; 88(8):753-61. PubMed ID: 20445955 [TBL] [Abstract][Full Text] [Related]
44. Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go. Rudick RA Ann Neurol; 2011 Feb; 69(2):234-6. PubMed ID: 21387367 [No Abstract] [Full Text] [Related]
46. Drifting fields of experimental allergic encephalomyelitis lesions in the vicinity of granulomato (diffusion of autoantigens?). Jindrak K; Werthamer S Exp Neurol; 1976 Feb; 50(2):259-75. PubMed ID: 1248549 [No Abstract] [Full Text] [Related]
47. Contemplating autoimmunity in the Aegean islands. Walker LS; Ziegler S; Becher B Nat Immunol; 2016 Mar; 17(3):218-20. PubMed ID: 26882250 [TBL] [Abstract][Full Text] [Related]
48. Immune pathogenesis of multiple sclerosis. Brain autoimmune reactivity and its control by neuronal function. Wekerle H Mult Scler; 1998 Jun; 4(3):136-7. PubMed ID: 9762662 [No Abstract] [Full Text] [Related]
49. Inflammation in multiple sclerosis--sorting out the gray matter. Calabresi PA N Engl J Med; 2011 Dec; 365(23):2231-3. PubMed ID: 22150043 [No Abstract] [Full Text] [Related]
50. IgLON5 autoimmunity and abnormal behaviours during sleep. Högl B; Heidbreder A; Santamaria J; Graus F; Poewe W Lancet; 2015 Apr; 385(9977):1590. PubMed ID: 25933285 [No Abstract] [Full Text] [Related]
51. Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. Khoury S; Bakshi R Ann Neurol; 2010 Dec; 68(6):778-9. PubMed ID: 21194148 [No Abstract] [Full Text] [Related]
52. New rat model recapitulates disabling grey matter damage in multiple sclerosis. Fyfe I Nat Rev Neurol; 2019 Apr; 15(4):185. PubMed ID: 30872811 [No Abstract] [Full Text] [Related]
53. α-Crystallin B autoimmunity and multiple sclerosis. Wood H Nat Rev Neurol; 2023 Jul; 19(7):387. PubMed ID: 37280293 [No Abstract] [Full Text] [Related]
54. Autoimmunity in multiple sclerosis need not be abnormal. van Noort JM Mult Scler; 2014 Jul; 20(8):1030-2. PubMed ID: 24368758 [No Abstract] [Full Text] [Related]
55. Sex hormone therapy in Multiple Sclerosis: A systematic review of randomized clinical trials. Shayestehfar M; Salari M; Karimi S; Vosough M; Memari A; Nabavi SM J Cent Nerv Syst Dis; 2024; 16():11795735231223411. PubMed ID: 38188227 [TBL] [Abstract][Full Text] [Related]
56. Microglia-derived CCL2 has a prime role in neocortex neuroinflammation. Errede M; Annese T; Petrosino V; Longo G; Girolamo F; de Trizio I; d'Amati A; Uccelli A; Kerlero de Rosbo N; Virgintino D Fluids Barriers CNS; 2022 Aug; 19(1):68. PubMed ID: 36042496 [TBL] [Abstract][Full Text] [Related]
57. Implication of Contactins in Demyelinating Pathologies. Kalafatakis I; Savvaki M; Velona T; Karagogeos D Life (Basel); 2021 Jan; 11(1):. PubMed ID: 33451101 [TBL] [Abstract][Full Text] [Related]